-
新生血管性青光眼(neovascular glaucoma,NVG)是一组以房角和虹膜出现的新生血管、眼球剧痛、眼压增高、视力下降等为主要特征的疾病,破坏性强,致盲率高,常继发于各种缺血缺氧性眼科疾病,如糖尿病视网膜病变、视网膜中央动/静脉阻塞、恶性黑素瘤、视网膜脱离等[1]。NVG属于难治性青光眼,目前国内外针对该病还没有形成统一的治疗规范,原则上需要控制原发病,抑制新生血管形成和控制眼压。抗血管内皮生长因子(VEGF)药物,如雷珠单抗、贝伐单抗、阿伯西普、康柏西普等,能通过抑制VEGF,有效抑制新生血管形成。小梁切除术是目前临床上常用的用于控制眼压的手术方式之一,可单独或联合其他手段用于治疗NVG。本研究就抗VEGF药物雷珠单抗和康柏西普与小梁切除术治疗NVG的疗效作一探讨。
-
注药前后2组间不同时点眼压差异均无统计学意义(P>0.05)。与注药前眼压相比,2组注药后差异均无统计学意义(P>0.05),术后1周、2周、3周、1个月均明显低于注药前和注药后(P < 0.01)(见表 1)。
分组 n 注药前 注药后 术后1周 术后2周 术后3周 术后1个月 F P MS组内 雷珠单抗组 23 40.12±9.46 38.66±8.37 15.69±3.73**## 15.82±3.08**## 15.31±4.32**## 17.18±7.56**## 78.13 < 0.01 43.127 康柏西普组 26 43.33±10.79 40.58±9.22 14.68±2.89**## 15.08±3.8**## 16.01±5.42**## 18.37±6.67**## 84.05 < 0.01 49.682 t — 1.10 0.76 1.07 0.74 0.50 0.59 — — — P — >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 — — — 组内配对t检验:与注药前比较**P < 0.01;与注药后比较##P < 0.01 表 1 2组病人不同时间点眼压比较(x±s;mmHg)
-
雷珠单抗组中,分别有1例病人视力在术后1周和1个月得到改善,1例在术后1个月视力恶化;康柏西普组中,2例视力在术后1周得到改善。2组病人治疗前后不同时点的视力差异均无统计学意义(P>0.05)(见表 2)。
分组 n BCVA χ2 P >0.1 0.02~0.1 指数 手动 注药前 雷珠单抗组
康柏西普组23
264
412
133
34
60.26 >0.05 注药后 雷珠单抗组
康柏西普组23
264
412
133
34
60.26 >0.05 术后1周 雷珠单抗组
康柏西普组23
265
611
113
34
60.31 >0.05 术后2周 雷珠单抗组
康柏西普组23
265
611
113
34
60.31 >0.05 术后3周 雷珠单抗组
康柏西普组23
265
611
113
34
60.31 >0.05 术后1个月 雷珠单抗组
康柏西普组23
266
610
112
35
60.16 >0.05 表 2 抗VEGF药物联合小梁切除术对NVG病人BCVA的影响(n)
-
雷珠单抗组术后19例(82.6%)虹膜新生血管逐渐消退,4例(17.4%)分别于术后1个月又出现新的新生血管。康柏西普组术后23例(88.5%)虹膜新生血管逐渐消退,3例(11.5%)均在术后1个月出现新的新生血管。2组虹膜新生血管消退及并发症差异无统计学意义(χ2=0.03,P>0.05)。
两种抗血管内皮细胞生长因子药物联合小梁切除术治疗新生血管性青光眼的疗效比较
Effect comparison of two anti-vascular endothelial growth factor drugs combined with trabeculectomy in the treatment of neovascular glaucoma
-
摘要:
目的比较两种抗血管内皮细胞生长因子(VEGF)药物(雷珠单抗和康柏西普)联合小梁切除术治疗新生血管性青光眼(NVG)的疗效和并发症。 方法选取接受治疗且术后至少接受1个月随访NVG 49例,根据使用不同抗VEGF药物,分为雷珠单抗组23例(23眼)和康柏西普组26例(26眼),观察2组治疗后的视力、虹膜新生血管消退情况。 结果2组不同时点眼压差异均无统计学意义(P>0.05),术后1周、2周、3周、1个月均明显低于注药前和注药后(P < 0.01)。2组治疗后的视力、虹膜新生血管消退及并发症差异均无统计学意义(P>0.05)。 结论玻璃体腔内注射抗VEGF药物联合小梁切除术是一种安全有效的治疗方式,在相似的疗效前提下,对新生血管性青光眼,康柏西普比雷珠单抗是一种更好的选择。 Abstract:ObjectiveTo compare the effects and complications between two kinds of anti-vascular endothelial growth factor(VEGF) monoclonal antibodies(ranibizumab and conbercept) in the treatment of neovascular glaucoma(NVG). MethodsFourty-nine NVG patients were divided into the leizumab group(23 cases) and conbercept group(26 cases) according to the treatment with different anti-VEGF drug, and the clinic data of two groups were retrospectively analyzed. ResultsThe differences of intraocular pressure(IOP) between two groups at different time-points were not statistically significant(P>0.05).The IOP in two groups after 1 week, 2 weeks, 3 weeks and 1 month of operation were significantly lower than that before and after injection(P < 0.01).After treatment, the differences of vision, iris neovascularization and complications between two groups were not statistically significant(P>0.05). ConclusionsThe intravitreal injection of anti-VEGF drugs combined with trabeculectomy is a safe and effective treatment.On the premise of similar efficacy, conbercept is a better choice than ranibizumab. -
Key words:
- neovascular glaucoma /
- ranibizumab /
- conbercept /
- trabeculectomy
-
表 1 2组病人不同时间点眼压比较(x±s;mmHg)
分组 n 注药前 注药后 术后1周 术后2周 术后3周 术后1个月 F P MS组内 雷珠单抗组 23 40.12±9.46 38.66±8.37 15.69±3.73**## 15.82±3.08**## 15.31±4.32**## 17.18±7.56**## 78.13 < 0.01 43.127 康柏西普组 26 43.33±10.79 40.58±9.22 14.68±2.89**## 15.08±3.8**## 16.01±5.42**## 18.37±6.67**## 84.05 < 0.01 49.682 t — 1.10 0.76 1.07 0.74 0.50 0.59 — — — P — >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 — — — 组内配对t检验:与注药前比较**P < 0.01;与注药后比较##P < 0.01 表 2 抗VEGF药物联合小梁切除术对NVG病人BCVA的影响(n)
分组 n BCVA χ2 P >0.1 0.02~0.1 指数 手动 注药前 雷珠单抗组
康柏西普组23
264
412
133
34
60.26 >0.05 注药后 雷珠单抗组
康柏西普组23
264
412
133
34
60.26 >0.05 术后1周 雷珠单抗组
康柏西普组23
265
611
113
34
60.31 >0.05 术后2周 雷珠单抗组
康柏西普组23
265
611
113
34
60.31 >0.05 术后3周 雷珠单抗组
康柏西普组23
265
611
113
34
60.31 >0.05 术后1个月 雷珠单抗组
康柏西普组23
266
610
112
35
60.16 >0.05 -
[1] 胡郑君, 胡红梅, 张亮. 玻璃体腔Bevacizumab注射后联合二联术治疗新生血管性青光眼[J]. 国际眼科杂志, 2015, 15(5): 892. [2] 史志洁, 张金嵩, 吕晓贝. 玻璃体内注射康柏西普联合手术治疗伴玻璃体积血的新生血管性青光眼[J]. 眼科新进展, 2016, 36(8): 751. [3] 徐韶琳, 王英, 苏冠方. 不同手术方式治疗新生血管性青光眼疗效观察[J]. 眼科研究, 2007, 25(9): 707. [4] KOBAYASHI S, INOUE M, YAMANE S, et al. Long-term outcomes after preoperative intravitreal injection of bevacizumab before trabeculectomy for neovascular glaucoma[J]. J Glaucoma, 2016, 25(3): 281. doi: 10.1097/IJG.0000000000000211 [5] SAITO Y, HIGASHIDE T, TAKEDA H, et al. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma[J]. Acta Ophthalmol, 2010, 88(1): 96. doi: 10.1111/j.1755-3768.2009.01648.x [6] GUPTA V, JHA R, RAO A, et al. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma[J]. Eur J Ophthalmol, 2009, 19(3): 435. doi: 10.1177/112067210901900318 [7] ZHANG M, ZHANG J, YAN M, et al. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys[J]. Mol Vis, 2008, 14(4): 37. [8] ROSENFELD PJ, SCHWARTZ SD, BLUMENKRANZ MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration[J]. Ophthalmology, 2005, 112(6): 1048. doi: 10.1016/j.ophtha.2005.01.043 [9] 蔡锡安, 彭惠. 两种抗VEGF药物治疗渗出性年龄相关性黄斑病变的疗效[J]. 国际眼科杂志, 2016, 16(8): 1501. [10] LIU L, XU YF, HUANG Z, et al. Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications[J]. BMC Ophthalmol, 2016, 16(1): 1. doi: 10.1186/s12886-015-0180-2 [11] LÜKE J, NASSAR K, LVKE M, et al. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma-results from a prospective interventional case series[J]. Graefes Arch Clin Exp Ophthalmol, 2013, 251(10): 2403. doi: 10.1007/s00417-013-2428-y